Editorials Ignored by the pharmaceutical industry and by public-private partnerships

The world's most neglected diseases

BMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7357.176 (Published 27 July 2002) Cite this as: BMJ 2002;325:176

This article has a correction. Please see:

  1. Gavin Yamey, assistant editor (gyamey@bmj.com)
  1. BMJ

    Infectious diseases can be considered “neglected” when there is a lack of effective, affordable, or easy to use drug treatments. As most patients with such diseases live in developing countries and are too poor to pay for drugs, the pharmaceutical industry has traditionally ignored these diseases. Over the past decade, however, the public sector, by creating favourable marketing conditions, has persuaded industry to enter into public-private partnerships to tackle neglected diseases such as malaria, HIV, and tuberculosis. Yet some infectious diseases—the world's “most neglected” diseases—are still being ignored not just by the pharmaceutical industry but also by public-private partnerships.

    Why have these partnerships ignored the most neglected diseases, such as kala-azar, Chagas' disease, and sleeping sickness? This question was explored at a recent meeting in New York, organised by Médecins sans Frontières.1 The answer lies in the social contract that exists between the public and private sectors.

    The public sector has decided to make it public policy to leave drug development in the hands of the pharmaceutical industry. This industry in turn invests almost exclusively in developing drugs that are likely to be marketable and profitable—drugs for conditions such as pain, cancer, heart disease, and baldness. Public policies, such as tax incentives and …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe